From a press release that came out earlier this week at Stockhouse:
CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the launch of PsyIndex.com, a free premier stock index site and research tool designed for investors, bankers, analysts, journalists and other market participants interested in following and profiting from the emerging multi-billion dollar psychedelics and mushroom industry. The PsyIndex aggregates and tracks the public markets performance of the industry together with associated private companies, breaking news, media coverage and events.
The psychedelics industry could capture a meaningful part of the $28.6 billion global antidepressant market over the coming years as research programs and clinical trials progress towards commercialized treatment solutions. Ketamine, Psilocybin, MDMA and other psychedelics could also play a leading role in treating other high profile medical conditions, including anxiety, post-traumatic stress disorder (PTSD), ADHD and addiction. Newly formed private and public companies focused on the drug development, patient interaction and ancillary segments of the industry have peaked investor interest.